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Abstract
Human leishmaniasis covers a broad spectrum of clinical manifestations ranging from self-
healing cutaneous leishmaniasis to severe and lethal visceral leishmaniasis caused among
other species by Leishmania major or Leishmania donovani, respectively. Some drug candi-
dates are in clinical trials to substitute current therapies, which are facing emerging drug-
resistance accompanied with serious side effects. Here, two cinnamic acid bornyl ester
derivatives (1 and 2) were assessed for their antileishmanial activity. Good selectivity and
antileishmanial activity of bornyl 3-phenylpropanoate (2) in vitro prompted the antileishma-
nial assessment in vivo. For this purpose, BALB/c mice were infected with Leishmania
major promastigotes and treated with three doses of 50 mg/kg/day of compound 2. The
treatment prevented the characteristic swelling at the site of infection and correlated with
reduced parasite burden. Transmitted light microscopy and transmission electron micros-
copy of Leishmania major promastigotes revealed that compounds 1 and 2 induce mito-
chondrial swelling. Subsequent studies on Leishmania major promastigotes showed the
loss of mitochondrial transmembrane potential (ΔΨm) as a putative mode of action. As the
cinnamic acid bornyl ester derivatives 1 and 2 had exhibited antileishmanial activity in vitro,
and compound 2 in Leishmania major-infected BALB/c mice in vivo, they can be regarded
as possible lead structures for the development of new antileishmanial therapeutic
approaches.
Introduction
Human leishmaniasis is a vector-borne parasitic disease that is caused by more than 20 species
of the protozoan genus Leishmania [1]. The term “leishmaniasis” covers a variety of clinical
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manifestations ranging from self-healing to lethal infections. Cutaneous leishmaniasis (CL)
causes substantial morbidity with an estimated annual incidence of 800.000 cases, whereas the
visceral form of leishmaniasis (VL) is responsible for about 300.000 new infections per year
with a total mortality rate of 30.000 [2]. Currently, the few clinically approved drugs against
human leishmaniasis are becoming more unreliable due to severe side effects [3] and the
appearance of drug resistance problems [4, 5]. Therefore, there is an urgent need for new thera-
peutic approaches against the most common forms of leishmaniasis.
Following the identification of antileishmanial lead compounds by means of in vitro assays,
well established animal models are usually chosen to investigate the potential of drug candi-
dates in vivo. BALB/c mice have been extensively used, mainly due to their susceptibility to a
variety of Leishmania species, and particularly for Leishmania (L.) major infection studies [6,
7].
For the last few years, many naturally occurring compound classes such as chalcones and
quinolines were found to have antileishmanial activity in vitro and in experimental mouse
models [8, 9]. Recently, a semi-pure fraction of a chloroform extract of Valeriana (V.) wallichii
with significant antileishmanial activities and with IC50 values lower than 10 μg/mL in addition
to an apparent apoptosis-like cell death induction were identified [10]. Further fractionation
resulted in caffeic acid bornyl ester exhibiting good antileishmanial activity against L.major
promastigotes [11]. This finding prompted the synthesis of a library of related compounds in
order to establish structure-activity relationships (SAR). In general, compounds having a
brenzcatechin moiety were found to be active, but also cytotoxic against host cells due to oxida-
tion and formation of a highly reactive Michael system, whereas analogue compounds without
the 3,4-dihydroxy substitution at the phenyl ring (e.g. compound 1) were still active but less
toxic [12]. Furthermore, the typical Michael system of the caffeic acid moiety could be omitted
to obtain an active but non-toxic phenylpropanoic acid ester 2 [12].
The present study aims to determine the effect of compound 2 treatment on CL in vivo and
to elucidate the cell death mechanism induced by both the compounds (1 and 2) in L.major
parasites. Our results suggest that the approach of using bornyl caffeate isolated from V. walli-
chii and related derivatives is efficient to identify and optimize antileishmanial lead structures
showing in vitro and in vivo activity towards L.major in BALB/c mice.
Material and Methods
Synthesis of compounds 1 and 2
(-)-Bornyl cinnamate (1) and (-)-bornyl 3-phenylpropionate (2) were synthesized as described
previously [12].
Leishmania strains and cultivation methods
The cloned virulent L.major parasite (strain: MHOM/IL/81/FE/BNI) was maintained by con-
tinuous passage in female BALB/c mice (Government of Lower Franconia, Germany, permis-
sion number: 55.2-2531.01-26/12). L.major amastigotes were isolated from lesions as
described previously [13] and promastigotes were grown in vitro in blood-agar cultures at
27°C, 5% CO2, and 95% humidity.
Luciferase-transgenic (Luc-tg) L.major has been generated as described previously [14].
The virulence of Luc-tg L.major was maintained by passage in female BALB/c mice and pro-
mastigotes were grown in vitro in blood agar cultures with addition of 50 μg/mL hygromycin B
using the same conditions as described above.
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L. donovani promastigotes (strain: MHOM/IN/1983/AG83) were obtained from the Indian
Institute of Chemical Biology, Kolkata, India. Promastigotes were cultured in Schneider’s insect
medium (Sigma-Aldrich Co., St. Louis, USA) as described elsewhere [15].
In vitro antileishmanial activity against Leishmania parasites and
cytotoxicity studies
Antiparasitic activities of compounds 1 and 2 dissolved in dimethyl sulfoxide (DMSO, E.
Merck, India) against L. donovani (AG83) promastigotes were determined by a quantitative
colorimetric assay using the 3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide
(MTT) (Sisco Research Laboratory, Mumbai, India) test as described elsewhere [16]. The com-
pounds were tested at concentrations of 10 μM, 50 μM, and 100 μM and IC50 values (concen-
tration of compound, which inhibited at least 50% cell metabolic activity) for each compound
were determined from respective dose–response curves using Origin 5.0 software (Microcal
Software, Inc., Northampton, MA, USA).
The activity of the two tested compounds 1 and 2 against L.major parasites was evaluated
using the colorimetric AlamarBlue assay as described previously [17]. The compounds were
tested at increasing concentrations ranging from 0.1 μM—100 μM for 24 h. AlamarBlue was
added for additional 48 h and the optical density was measured with Multiskan Ascent
enzyme-linked immunosorbent assay (ELISA) reader (Thermo Electron Corporation,
Dreieich, Germany) using a test wavelength of 540 nm and a reference wavelength of 630 nm.
Absorbance in the absence of compounds was set as 100% parasite growth.
A detailed protocol of antileishmanial investigations against intracellular L.major amasti-
gotes residing within bone marrow-derived macrophages (BMDM) is described elsewhere
[14]. Briefly, 2 × 105/ml BMDM were infected with Luc-tg L.major promastigotes at a ratio of
1:15 for 24 h. These infected BMDM were cultured in the absence or presence of increasing
concentrations of the tested compounds 1 and 2 for 24 h prior to the supplement of Britelite
plus (PerkinElmer, Waltham, MA, USA) for 5 min. Britelite plus is a very sensitive assay for
the quantification of firefly luciferase in Leishmania parasites [14]. The luminescence was mea-
sured using a Victor X Light 2030 luminometer (PerkinElmer, Waltham, MA, USA).
BMDM were generated in complete RPMI medium as described previously [14]. On day
six, the cytotoxicity against 2 × 105 cells/ml was tested at increasing concentrations of com-
pounds 1 and 2 for 48 h. Human embryonic kidney HEK 293 T cells (ATCC, Wesel, Germany)
were cultured in Dulbecco´s Modified Eagle Medium (DMEM) (Life Technologies, Darmstadt,
Germany), with 10% FCS (PAA Laboratories, Germany). According to the standard operating
procedures (SOP) within the Collaborative Research Center 630 (SFB 630) 2 × 104 HEK 293 T
cells/ml were tested at increasing concentrations of compounds 1 and 2 for 48 h. Human liver
carcinoma HepG2 cells (ATCC) were cultured in RPMI medium (Gibco) with 10% FCS.
1 × 105 cells/ml HepG2 were tested at increasing concentrations of 1 and 2 for 72 h according
to the SOPs. The AlamarBlue assay was performed as described above for L.major parasites.
Ethics statement
All L.major animal experiments were designed and performed in strict accordance with the
German Animal Welfare Act (TierSchG) according to the experimental guidelines and proce-
dures approved by the government of Lower Franconia, Germany (permission number: 55.2-
2531.01-25/13). The L.major parasite (strain: MHOM/IL/81/FE/BNI) was originally isolated
from an Israeli patient with oriental sore in 1981 and was received from the Bernhard-Nocht-
Institute, Hamburg (Germany) [18].
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The L. donovani parasite (strain: MHOM/IN/1983/AG83) was originally isolated from a
North Indian VL patient unresponsive to treatment with sodium stibogluconate and was
received as a generous gift from Prof. Shyam Sundar, Institute of Medical Sciences, Banaras
Hindu University, India [19].
Mice
Naïve female inbred BALB/c mice weighing 16–18 g were purchased (Charles River Breeding
Laboratory, Sulzfeld, Germany), housed in groups of four and were given five days to acclimate
prior to treatment. At the onset of the L.major infection studies the mice were 6–8 weeks of
age. All mice were kept under specific pathogen-free conditions in individually ventilated cages
(IVC). Environmental conditions were a temperature of 21°C ±2°, humidity of 50% ±10%,
lighting of 60 lux and a 12:12 light: dark cycle with lights on at 7 a.m. and off at 7 p.m. Animals
were housed in 391×199×160 mm cages (Techniplast GmbH, Hohenpeißenberg, Germany;
Seal Safe PLUS cages X-TEMP PPSU) and given access to mouse maintenance food (ssniff Spe-
zialdiaeten GmbH, Soest, Germany; R/M-H maintenance food) and water ad libitum. Environ-
mental enrichment included bedding (Abedd LAB and VET Service GmbH, Vienna, Austria;
Espe-classic—H0234-40), and one handful of paper tissue nesting material. During housing,
animals were monitored daily for health status. No adverse events were observed.
In vivo antileishmanial activity against L.major
Female BALB/c mice (11 per group; three groups in total) were infected with 2 × 105 L.major
promastigotes in 30 μL phosphate-buffered saline (PBS) into the right hind footpad under iso-
flurane inhalation anaesthesia using the UniVet Porta system (Groppler, Deggendorf, Ger-
many) [7]. The clinical manifestation of L.major infection was monitored twice a week by
determination of the body weight (g) and footpad size (mm) of the infected (iFP) and the non-
infected footpad (niFP) serving as negative control. The footpad swelling describes the differ-
ence in mm between the iFP and niFP of individual mice. Three weeks post infection (p.i.) the
mice were randomly divided into three groups of 11 for different treatment regimens. On day
21, 25, and 28 p.i. the respective groups were either left untreated, treated intraperitoneally (i.
p.) with 100 μl of solvent (infected, 50% DMSO/PBS) or 100 μl 50 mg/kg/day of compound 2
in 50% DMSO/PBS. This high dose of compound 2 was chosen to identify its antileishmanial
in vivo efficacy in L.major-infected BALB/c mice. The close monitoring of body weight and
footpad swelling was continued until the end of experiment. On day 35 p.i. mice were sacrificed
by CO2 inhalation and single cell suspensions from the iFP, draining popliteal lymph nodes
(pLN) and spleens were obtained. The parasite burden was determined by limiting dilution
assays as described previously [20]. It was not necessary to apply any analgesics or anaesthetics
during the animal trials. Compound 2 did not have any strong side effects.
Cultivation conditions for compound 1- and compound 2-induced
phenotypic changes in L.major promastigotes
L.major parasites harvested from blood agar cultures were washed twice with Dulbecco’s phos-
phate-buffered saline (DPBS; Invitrogen, Darmstadt, Germany) and centrifuged at 3.000 × g
for 10 min. The pellet was suspended in RPMI 1640 medium at a final concentration of 1 × 108
cells/ml. Cells were treated with 1% DMSO, 122.7 μMmiltefosine (1-hexadecylphorylcholine;
apoptosis inducer), or 100 μM of the tested compounds 1 and 2 in a final volume of 200 μl in
96 well plates. Samples were incubated at 27°C in 5% CO2 for several time points between 30
min and 24 h. Transmitted light microscopic, transmission electron microscopic (TEM), and
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flow cytometric techniques were used to find phenotypic patterns caused by the treatment with
the tested compounds.
Diff-Quik staining for transmitted light microscopy
After incubation for 30 min, 1 h, 2 h, 4 h, and 24 h in the presence of the tested compounds 1
and 2, promastigotes were harvested and centrifuged in a Cytospin 3 centrifuge (Shandon,
Frankfurt, Germany) on microscope slides at 253 × g for 5 min at room temperature (RT).
Cytospin preparations of cells were stained using the Differential Quick Stain (Diff-Quik) dye
(Medion Diagnostics AG, Duedingen, Switzerland), according to the manufacturers’ protocol
with some modifications. Diff-Quik stains the leishmanial nuclei and the kinetoplasts dark
purple and the cytoplasm light purple allowing the observation of phenotypic changes within
the parasite. Briefly, air-dried cells were fixed by dipping the slides 5 times for 3 seconds in fixa-
tive solution. Subsequently the slides were stained with Solution I following Solution II (from
Diff-Quik kit) and air-dried between each staining steps. Finally, the samples were rapidly
dipped once in ultra-pure water (produced by a TKA purification system apparatus, Niederel-
bert, Germany) to remove excessive staining solutions. The air-dried cells were analyzed by
transmitted light microscopy under a 50× objective on a Nikon ECLIPSE 50imicroscope
equipped with a digital camera (Nikon, Tokyo, Japan). The images were processed using NIS
Elements D software (Nikon).
Transmission electron microscopy (TEM)
L.major promastigotes were incubated for 2 h in the presence of DMSO, 100 μM of compound
1 and compound 2, respectively. After the incubation period, the parasites were harvested, con-
trasted and embedded following the procedure described previously [21]. Ultrathin sections
were mounted on 300-mesh grids, stained with uranyl acetate and lead citrate, and analyzed
with an EM 10 transmission electron microscope (Carl Zeiss AG, Oberkochen, Germany). To
describe morphological changes in a statistical manner, six photographs with approximately 50
cells were taken and the percentage of cells with swollen mitochondria per treatment was
determined.
MitoTracker staining of L.major promastigotes
L.major promastigotes were harvested from blood-agar cultures and washed twice with DPBS
(900 × g for 5 min at RT). 2 × 106 promastigotes were dissolved in 180 μl RPMI complete
medium and seeded in a 96 well plate. Parasites were incubated with 20 μL of compound 1
(final concentration: 100 μM), compound 2 (final concentration: 100 μM) and with 20 μL of
DMSO, respectively, for 30 min, 45 min, 60 min, or 120 min at 27°C in a 5% CO2. After incuba-
tion 2 μl of MitoTracker Red CMXRos (final concentration: 100 mM) (Life Technologies,
Darmstadt, Germany) was added for 15 min at 27°C. Samples were directly acquired using a
MACSQuant Analyzer (Miltenyi Biotech, Bergisch Gladbach, Germany) and MitoTracker-
positive parasites were analyzed using MACS Quant Analyzing software.
Determination of the cell death phenotype by flow cytometric analysis
The loss of membrane integrity and translocation of phosphatidylserine (PS) to the outside of
the cellular membrane can be determined by annexin V (AV) and propidium iodide (PI) stain-
ing. Double staining with AV-fluorescein isothiocyanate (FITC) and PI during flow cytometry
analysis leads to discrimination between four populations: double negatives or alive cells (AV-/
PI-), double positive or late necrotic/late apoptotic cells (AV+/PI+), PI-positive and AV-
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negative or early necrotic cells (AV-/PI+), and PI-negative and AV-positive or early apoptotic
cells (AV+/PI-) [22, 23].
Parasites were harvested after incubation for 6 h, 10 h, and 24 h in the presence of com-
pounds 1, 2 and miltefosine (Cayman Chemical Company, MI, USA), respectively, the latter
serving as positive control for the induction of apoptotic cell death. DMSO was used as solvent
control. Cell staining was performed using an AV-FITC Apoptosis detection kit (Sigma-
Aldrich, Saint Louis, MO, USA). Cells were harvested, washed and suspended in 500 μL of
binding buffer, 5 μL of AV-FITC and 10 μl of PI. The cells were incubated for 10 min in the
dark at RT. Finally, stained samples were immediately analyzed by flow cytometry using
MACSQuant analyzer or a flow cytometer (Becton Dickinson, San José, CA, USA).
Statistical analyses
Data were analyzed using the GraphPad Prism 5 (San Diego, USA) software and values are
given as mean ± standard deviation (SD). Footpad swelling of Leishmania-infected mice as
well as the parasite burden of infected tissues is displayed per individual mouse with 11 mice
per group. The unpaired t-test was used to compare two independent groups. Differences were
considered significant at , p<0.005.
Results
Compounds 1 and 2 revealed antileishmanial activity against L.major
and L. donovani
For the initial evaluation of the antileishmanial activity of compounds 1 and 2, a MTT reduc-
tion and an AlamarBlue assay with L. donovani and L.major parasites were employed, respec-
tively. The cytotoxicity effects of the compounds were investigated in BMDM, HEP G2, and
HEK 293T cells (Fig 1). Compound 1 showed the best activity against L. donovani promasti-
gotes as well as L.major amastigotes and promastigotes (Fig 1). The half maximal inhibitory
concentrations (IC50) for compound 1 were between 39.6 μM against L.major promastigotes
and 10.9 μM against L.major amastigotes, being in the range of miltefosine used as a positive
control with an IC50 value of 36.2 μM against promastigotes and 33 μM against amastigotes
[12]. The cytotoxicity was variable for the three tested cells up to the highest dose of 100 μM.
50% of growth inhibition was not evident after treatment of L. donovani promastigotes with
the bornyl 3-phenylpropanoate (compound 2) with a dose up to 100 μM, but after treatment of
L.major promastigotes and amastigotes at 50.2 μM and 89.1 μM, respectively.
Interestingly, no cytotoxicity effects against host cell lines were found for the three cell types
up to 100 μM, whereas miltefosine displayed an IC50 value of 65.5 μM against BMDM.
The determination of IC50 values showed strain-specific differences. The cytotoxicity
against host cells in compound 1-treated cells was reduced after omitting the Michael system
from this compound resulting in compound 2, with a moderate activity against L.major pro-
mastigotes and amastigotes.
Compound 2 exhibited antileishmanial activity against L.major infection
in BALB/c mice
Since compound 2 exhibited no detectable cytotoxicity against the tested mammalian cell types
but showed antileishmanial activity against L.major parasites only (Fig 1), the effect of this
compound on L.major-infected BALB/c mice was investigated. As the translation from in vitro
findings to in vivo efficacy is the bottleneck in successful drug research, an experimental Leish-
mania-infection model was chosen to provide evidence for their antileishmanial activity in
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vivo [24]. Severe swelling and lesion development at the site of infection with ascending para-
site dissemination into organs during the onset of infection characterizes this CL infection
model [25]. An established CL infection in non-healing BALB/c mice can be observed from
week three post infection and is characterized by significant footpad swelling and elevated par-
asite burden [7]. To investigate the antileishmanial effect in an already established L.major
infection, compound 2 was assessed for its activity in L.major-infected female BALB/c mice
(Fig 2). Consequently, the treatment regimen was started on day 21 with repetitions on days 25
and 28 p.i. to evaluate the efficacy of a short-term treatment regimen [26].
L.major-infected BALB/c mice treated i.p. with 50 mg/kg/day of compound 2 on days 21,
25, and 28 showed reduced footpad swelling compared to untreated or solvent control-treated
mice (Fig 2A). Significant reduction in footpad swelling was already achieved after the second
Fig 1. Determination of cytotoxicity and IC50 values against Leishmania parasites.
doi:10.1371/journal.pone.0142386.g001
Fig 2. Compound 2 treatment mediates recovery from L.major-induced disease progression in
BALB/c mice. Female BALB/c mice (total: n = 33) were infected with 5 × 106 L.major promastigotes into the
right hind footpad. On d 21 post infection BALB/c mice were either treated intraperitoneally with 50 mg/kg
compound 2 (&) (n = 11), 50% DMSO/PBS (□) (n = 11) or left untreated (▲) (n = 11). Individual treatment was
repeated on d 25 and d 28 post infection. A. Footpad swelling (difference between infected and non-infected
footpad in mm) and B. body weight (g) was determined twice a week to monitor clinical manifestation of CL.
n = number of animals.
doi:10.1371/journal.pone.0142386.g002
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administration of compound 2 on day 25 compared with the footpad swelling of untreated or
solvent-treated mice. The triple administration of compound 2 resulted in a reduction of the
foot pad swelling, indicating a recovering phenotype upon 28 days post infection. In contrast,
an ongoing infection as observed in untreated or solvent-treated mice was accompanied with
an increasing footpad swelling. Infected but untreated BALB/c mice reflected the manifesta-
tions of experimental CL, characterized by footpad swelling of ~3 mm difference between
infected and non-infected footpad (Fig 2A) and significant loss of body weight (Fig 2B) after
five weeks post infection. Mice treated with the solvent control showed also clinical manifesta-
tions with footpad swelling and loss of body weight, similar to untreated mice. The clinical
manifestation and progression of leishmaniasis in the two control groups was also associated
with loss of body weight, whereas the body weight of infected mice treated with compound 2
was not affected during the treatment regimen (Fig 2B).
Progressing Leishmania infection in BALB/c mice is associated with elevated parasite bur-
dens within infected tissues and organs, whereas a recovering phenotype is associated with
reduced parasite levels. Limiting dilutions assays (LDA) confirmed high parasite burden in
infected footpads (Fig 3A), at the site of infection-draining popliteal lymph nodes (Fig 3C), and
spleens (Fig 3D) of diseased mice. The recovering phenotype in compound 2-treated BALB/c
mice correlated with a ~100 fold reduced parasite burden within the infected footpads, a
~10.000 fold reduced parasite burden within the popliteal lymph nodes (Fig 3C). The parasite
burden in the spleen was only numerically reduced, due to a low sample number (Fig 3D). The
photographic documentation of three exemplary infected footpads per group demonstrated
the clear difference between a compound 2-treated recovering phenotype and the diseased
footpads of control mice at the end of the experiment five weeks post infection (Fig 3B).
Taken together, the short-term treatment of L.major-infected BALB/c mice with compound
2 was successful in terms of the observed recovery of footpad swelling and parasite burdens
compared to untreated mice (Figs 2 and 3).
Rapid changes in cell morphology and induction of mitochondrial
swelling were mediated by compounds 1 and 2 in L.major
promastigotes
Since IC50 values and cytotoxicity assays for compounds 1 and additionally in vivo efficiency
for compound 2 revealed antileishmanial activity and relatively good selectivity, the effect of
these two compounds against L.major promastigotes was further investigated. First, potential
changes of the cell morphology induced by the compounds 1 and 2 were studied by means of
transmitted light microscopy. The visual examination of promastigotes incubated with com-
pounds 1 and 2 revealed that the early rounding of cell shape during the first hour of incuba-
tion became more prominent over time when compared to control cells (Fig 4). Beside changes
in the cell shape of compound-treated promastigotes, the formation of intracellular vacuole-
like structures has also been observed within the first hour leading to larger aggregates of cells
in vacuolization processes compared to control cells (intracellular vacuoles are better shown in
insets of Fig 4). After treatment with miltefosine, compound 1 and 2 for 24 h rounding of
shape and shrinkage of almost all cells was observed. No morphological changes were evident
in the control cells along the 24 h incubation period (Fig 4). Whereas the apoptosis inducer
miltefosine promoted morphological changes and cell disruption after 2 h of treatment, com-
pounds 1 and 2 induced vacuolization and changes in cell morphology. This phenotype was
observable in compound 1-treated promastigotes just after 30 min and in compound 2-treated
promastigotes after 1 h. The antileishmanial effect of compound 1 and 2 as seen by in vitro and
in vivo studies together with the transmission light microscopic investigations identified the
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potential mode of action against L.major parasites as a result of changes in the cell morphology
and formation of vacuole-like structures within the parasite.
The observation of prominent vacuoles and swelling of parasites prompted the elucidation of
the origin of those vacuoles by investigating the ultrastructure using TEM. Compared to DMSO-
treated promastigotes showing typical morphological characteristics (Fig 5A), parasites treated
with compound 1 or 2 displayed large intracellular vacuoles (Fig 5B and 5C) as seen in the light
microscopic pictures above (Fig 4). Leishmania belongs to the class of Kinetoplastida, which are
characterized by the presence of a DNA-containing kinetoplast within the giant single mitochon-
drion being usually localized near the flagellar pocket of the parasite [27]. Considering this, it can
be postulated that compound 1 and 2 induced alterations in the ultrastructure of the mitochon-
dria in L.major promastigotes, as the kinetoplast DNA was clearly visible within the observed
vacuoles (Fig 5B and 5C). A difference in percentage of swollen mitochondria in compound- or
DMSO-treated parasites was noted. None of the DMSO-treated parasites displayed swollen
mitochondria, whereas compound 1 and 2 induced mitochondrial swelling in 39% or 36% of
counted parasites after 2 h, respectively. Additionally, compound 1- and 2-treated promastigotes
(Fig 5B and 5C) displayed a slimmer cell body compared to the DMSO-treated control parasites
(Fig 5A). The origin of this phenotype is unclear and must be investigated in further studies.
So far, the leishmanicidal mode of action of the compounds 1 and 2 is most probably due to
alterations of the mitochondrial ultrastructure through marked swelling and loss of matrix
Fig 3. Compound 2 treatment of L.major-infected BALB/c mice is associated with reduced parasite
burden in infected tissues and organs. Female BALB/c mice (n = 33) were infected with 5 × 106 L.major
promastigotes into the right hind footpad. Treatment regimen started on d 21 post infection either using 50%
DMSO/PBS (□) (n = 11), 50 mg/kg compound 2 (&) (n = 11) or mice were left untreated (▲) (n = 11). A. At the
end of experiment on d 35 all mice (n = 33) were sacrificed and the parasite burden of the infected footpads
(iFP) (n = 9) was determined using Limited Dilution Assays (LDA). B. Photographic documentation of the
infected footpads of three exemplary mice per group shall reveal the severity of disease progression in non-
healing mice and the control of clinical manifestation in compound 2-treated BALB/c mice. C. The parasite
burden of the infection site-draining popliteal lymph nodes (pLN) of individual mice (n = 9) or D. spleens of
individual mice (n = 6) was determined using LDA. n = number of animals; ** p<0.005; differences in parasite
load between 50%DMSO/PBS-treated and compound 2-treated animals did not reach statistical significance
for D.
doi:10.1371/journal.pone.0142386.g003
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content, resulting in cell death of the L.major parasite. Other organelles within the parasite
seemed not to be affected by these two compounds, as i.e. the nucleus and other contrasted
organelles showed typical morphology.
Antileishmanial activity of compounds 1 and 2 was attributed to changes
in the mitochondrial transmembrane potential of L.major
The mitochondrial transmembrane potential was investigated as compound-induced mito-
chondrial dysfunction would lead to cell death of Leishmania parasites and could explain the
antileishmanial activity of the compounds 1 and 2 tested against L.major.
Fig 4. Changes in cell morphology in L.major promastigotes upon treatment. Compound 1 and 2
induce parasite swelling and vacuolization of L.major promastigotes at very early time points. L.major
promastigotes were treated with solvent control (1% DMSO), miltefosine (122.7 μM), compound 1 (100 μM),
and 2 (100 μM) for 30 min, 1 h, 2 h, 4 h, and 24 h. Cytospin preparations of the cells were stained with Diff-
Quik dye and analyzed by transmitted light microscopy under 50× objective. “Plus” symbol (+) was used to
represent changes in morphology; two (++) and three (+++) symbols were used as a reference for the
severity of the phenotype induced by the different tested compounds and the black arrows to indicate the
presence of vacuole-like structures. Black bar indicates 20 μm.
doi:10.1371/journal.pone.0142386.g004
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For this reason, L.major promastigotes were treated either with DMSO or with compound
1 or 2 for 30 min, 45 min, 60 min, and 120 min prior to MitoTracker Red CMXRos fluoromet-
ric staining (Fig 6). As the accumulation of MitoTracker Red CMXRos indicates functional
mitochondria, alterations of its function were detected over time in compound-treated L.
major promastigotes. A significant drop in MitoTracker-positive cells has been observed in
compound 1-treated parasites compared to parasites treated with DMSO that were set as 100%
functional mitochondria (Fig 6). The reduction of MitoTracker-positive cells after 60 min to
75% indicated alterations of mitochondrial functions that are becoming more prominent after
120 min of compound 1 treatment (63%).
Fig 5. Treatment with compound 1 or 2 inducesmitochondrial swelling in L.major promastigotes.
Ultrastructural alterations of mitochondria in compound 1- and compound 2-treated L.major promastigotes
were detected by TEM. A. L.major promastigotes were incubated for 2 h with DMSO-containing RPMI
medium and served as solvent control. B and C show TEM pictures of L.major promastigotes treated for 2 h
with 100 μM compound 1 or 100 μM compound 2, respectively. Two TEM pictures of characteristic parasites
are shown per sample. FP, flagellar pocket; N, nucleus; arrow, kinetoplast; white asterisk, mitochondrion;
black asterisk, swollen mitochondria. Black bar indicates 1 μm.
doi:10.1371/journal.pone.0142386.g005
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Similar to these observations, also compound 2-treatment altered the mitochondrial func-
tion of the parasite, as after 60 min and 120 min 75.2% and 60.2% MitoTracker-positive cells
were observed, respectively (Fig 6). Differences between DMSO- and compound-treated pro-
mastigotes have been observed as early as 60 min. As MitoTracker Red CMXRos stains the
mitochondria of live cells and its accumulation depends on the mitochondrial transmembrane
potential it can be concluded that treatment with these compounds mediated a membrane
depolarization in L.major promastigotes as a decreased accumulation of MitoTracker was
observed.
These results support the hypothesis that the antileishmanial activities of the compounds
tested in the present study are mitochondria-associated as a significant depolarization of the
mitochondrial transmembrane potential was observed in compound-treated L.major
promastigotes.
Loss of cell membrane integrity in L.major promastigotes because of
compound 1- and 2-treatment
The type of cell death induced by the compounds 1 and 2 was investigated using flow cyto-
metric approaches. Since the translocation of PS to the outside of the cellular membrane with-
out simultaneous loss of membrane integrity represents one of the features of early apoptosis
in mammalian cells [28], staining with AV (binds to PS) and PI (DNA-binding) was applied to
discriminate between four Leishmania populations as defined elsewhere [29]: live (AV-/PI-),
necrotic/late apoptotic (AV+/PI+), necrotic (AV-/PI+) and early apoptotic cells (AV+/PI-) using
Fig 6. The tested compounds 1 and 2 affect mitochondrial integrity andmembrane potential.
Mitochondrial integrity of compound-treated L.major promastigotes was investigated using flowcytometric
determination of MitoTracker Red CMXRos accumulation within active organelles. L.major promastigotes
were incubated in 1% DMSO or treated with 100 μM compound 1 or 2 for indicated time points prior to
MitoTracker Red CMXRos staining. MitoTracker-positive cell populations were determined by histograms
analysis and were presented as percentage of control cells (set as 100%, inserted line).
doi:10.1371/journal.pone.0142386.g006
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per definition miltefosine-treated parasites as positive control for apoptosis induction in Leish-
mania [30].
After exposure of L.major promastigotes to bornyl cinnamate (1) and bornyl 3-phenylpro-
panoate (2) for 24 h, a percentage of only 33% and 21% cells were alive (AV-/PI-), respectively,
whereas at the same time under normal growth conditions 71% and 79% of cells were unaf-
fected und alive (Fig 7). Compound-mediated cell death was found to increase over time. Com-
pound 1 treatment for 24 h resulted in increased cell permeability in 30% of all cells being
characterized as necrotic (AV-/PI+) whereas additional binding of AV to the parasites surface
was observed in 33% of all treated cells, leading to necrotic/late apoptotic (AV+/PI+) cells (Fig
7). These phenotypes increased over time, especially between the late time points from 10 h to
24 h of incubation. Interestingly, compound 2 induced a broad spectrum of phenotypes; after
24 h of treatment 24% of all cells showed per definition a necrotic (AV-/PI+), 19% per defini-
tion an early apoptotic (AV+/PI-), and 37% per definition a necrotic/late apoptotic cell death
phenotype (AV+/PI+) (Fig 7). These phenotypic effects increased over time and were predomi-
nant after 24 h of incubation.
The presence of miltefosine induced a strong affinity of the parasitic surface towards AV in
88% of the L.major promastigotes within 24 h. Between 6 h and 24 h a substantial shift from
8% to 13% of early apoptotic cells (AV+/PI-) and a shift from 45% to 75% of necrotic/late apo-
ptotic cells (AV+/PI+), respectively, was observed (Fig 7). Miltefosine is described as an inducer
of early apoptosis in L.major using AV as read out [30]. Here, miltefosine induced a broad
spectrum of cell deaths with a predominant late necrotic/late apoptotic phenotype (AV+/PI+).
In summary, investigations in L.major promastigotes treated with bornyl cinnamate (1)
and bornyl 3-phenylpropanoate (2) for 24 h revealed their antileishmanial in vitro activity. Per
definition, compound 1 induced a necrotic cell death phenotype and compound 2 a miltefo-
sine-like cell death being per definition associated with elevated levels of early apoptotic cells.
The mechanism underlying the antileishmanial activity of compound 1 and 2 is associated
with mitochondria deformation and inhibition of its transmembrane potential with the conse-
quence of cell death as defined by the loss of membrane integrity in L.major promastigotes.
Discussion
Although leishmaniasis is one of the infectious diseases causing 20.000 to 30.000 deaths each
year, it still belongs to the tropical neglected diseases [1]. Indeed, there is a huge clinical need,
but no adequate treatment is available against leishmaniasis, mainly because the efficacy of the
chemotherapy is limited by the continuous development of drug resistance to the first-line
drugs [4]. Traditionally, different cultures around the world have been using native plants for
treatment of systemic forms of leishmaniasis through oral administration of the crude extracts,
while the cutaneous infections have been treated with topical preparations of the same. There-
fore, the development of new antileishmanial therapies could involve the use of compounds
present in plants of the endemic zones of leishmaniasis.
The majority of drug candidates with promising in vitro activity are either toxic or not effi-
cient in experimental animal models. Those models are widely used to evaluate the antileish-
manial efficacy of a new treatment with regard to the route of drug administration in
correlation to the site of infection, and the treatment regimen. Among a pool of animal models,
mostly mice are used for antileishmanial drug studies [31]. Some of the advantages of using
inbred mice are the high reproducibility of the infection, the need of only few amounts of the
tested drugs due to the small weight of the mice, and the contemporary evaluation of the drug
efficacy within 2–5 weeks. L.major infection studies in BALB/c mice are most commonly cho-
sen in drug discovery studies against experimental CL, as BALB/c mice are highly susceptible
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Fig 7. Compound-associated cell death is time-dependent. L.major promastigotes were treated with
solvent control (1% DMSO), apoptosis inducer miltefosine (122.7 μM), compound 1 (100 μM), and 2 (100 μM)
in a time course experiment for 6 h, 10 h, and 24 h. Cells were harvested, stained with AV and PI and
subsequently analyzed by flow cytometry. Analysis for compound 2 was performed in an independent
experiment. Percentage for each quadrant is written below the corresponding dot blot figure. Lower-left (LL):
live cells (AV-/PI-); upper-left (UL): early necrotic cells (AV-/PI+); upper-right (UR): necrotic/late apoptotic cells
(AV+/PI+); and lower-right (LR): early apoptotic cells (AV+/PI-).
doi:10.1371/journal.pone.0142386.g007
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to the infection with no spontaneous recovery [32]. The cutaneous manifestation of a L.major
infection is accompanied by footpad swelling at the site of infection. A reduction of swelling
after drug administration is frequently associated with therapeutic elimination of parasites in
the footpad and therefore used as first clinical readout for drug efficacy. However, foot pad
swelling characterizes only indirectly the therapeutic effect. Theoretically, the reduction of
inflammation can be uncoupled from the parasite burden in the infected footpad. Therefore, it
is very important to determine the parasite burden directly within the infected foot pad and the
inner organs of mice by LDA assay.
During this study we showed for the first time that phenylpropanoic acid bornyl ester (2)
was efficient to treat Leishmania infections in vivo. Compound 2 tested against L.major in
BALB/c mice was highly efficient, as the susceptible BALB/c mice showed a healing phenotype
with reduced footpad swelling and parasite burdens. After a promising healing phenotype was
observed in mice treated with compound 2 and the lack of apparent side effects in vivo, we fur-
ther investigated the antileishmanial mechanism of action by in vitro approaches.
We first investigated cell morphological changes in promastigotes of L.major upon treat-
ment with the compounds 1 and 2 and compared them with the effect induced by miltefosine.
Presence of vacuole-like structures was evident for L.major promastigotes treated with the
tested compounds and a massive cell death was visible after 24 h of incubation as compared to
miltefosine-treated parasites.
Moreover, TEM revealed that the vacuole-like structures present in promastigotes of L.
major after treatment with compound 1 and 2 corresponded to swollen mitochondria contain-
ing the kinetoplast DNA. Previous studies have shown that after treatment of L.major promas-
tigotes and amastigotes with licochalcone A, a structurally similar constituent of roots and
rhizomes of different plants, mitochondria of the cells were swollen as observed by electron
microscopy [33]. Recent studies demonstrated that the effect of many antileishmanial drug
candidates led to mitochondrial destabilization of the Leishmania parasite [34, 35]. These find-
ings support the approach of the identification and evaluation of mitochondria-targeting drug
candidates, as mitochondrial integrity and functionality is essential for Leishmania survival
[36, 37].
The two compounds tested in the present study were found to induce cell death in L.major
promastigotes through a combination of multiple features, such as shrinking of cells, mito-
chondrial swelling and loss of cell membrane integrity. Cell death is mainly defined by either
the loss of cell membrane integrity as demonstrated by the incorporation of the vital dye PI or
the degradation into distinct apoptotic bodies and vesicles [38]. The loss of membrane integrity
has been shown by PI incorporation into compound 1- and 2-treated L.major promastigotes
whereas apoptotic body formation within the parasites was not observed by TEM. Regulated
cell death mechanism like apoptosis is described for mammalian cells based on the specificity
of AV to its ligand PS [39], consequently serving as a specific marker for apoptosis. It is contro-
versially discussed whether AV is a suitable marker for regulated cell death in Leishmania para-
sites [40, 41]. One reason for this concern is that PS was not yet identified in membrane
fractions and lipid extracts, if at all in very low levels of L.major promastigotes [42]. Further-
more, it has been shown that PS is not the only ligand for AV, but also phospholipids like
phosphatidylethanolamine and phosphatidylinositol are reported to be recognized by AV on
the cell surface of Leishmania [42]. Additional investigations on molecular mechanisms could
define appropriate Leishmania-specific readouts for regulated or unregulated cell death mecha-
nisms [40]. Our flow cytometry analysis data suggested that compound 1- and 2- treated Leish-
mania promastigotes underwent apoptosis and necrosis, respectively. A similar result with
both kinds of cell death was observed after treatment with miltefosine, which is a well-known
apoptosis inducer in Leishmania parasite [30]. However, there is an ample discussion if an
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apoptotic cell death really exists in Leishmania parasites. Regarding this controversy it has
been suggested by Proto and colleagues [40] to classify protozoan cell death as unregulated cell
death as long as no molecular signaling mechanism proves regulated cell death processes. Tak-
ing these concerns into account, the antileishmanial activity of the compounds 1 and 2 leading
to cell death is definitely based on severe mitochondrial alterations and the loss of the mito-
chondrial transmembran potential (ΔCm).
Beside target-based drug design, plant-derived compounds with antileishmanial activity
have been described. Extracts from various plants like Croton cajucara [43, 44], Zanthoxylum
chiloperone [45], Chinese licorice [46], and Pera benensis [47] have proven in vitro and in vivo
activities against different strains of Leishmania. Apparently, the cytotoxicity of naturally
derived compounds against host cells represents one obstacle of drug development [48]. V.
wallichii-derived extracts possess a broad range of antimicrobial activity against e.g. Staphylo-
coccus aureus, Bacillus subtilis, and Escherichia coli [49, 50]. Antiparasitic activity of V. wallichii
chloroform root extracts was explored in studies against Leishmania, where significant antil-
eishmanial activity against L. donovani and L.major promastigotes and intracellular L.major
amastigotes was identified [10]. Leaf extracts from Pluchea spp., belonging to the class of Aster-
ids like V. wallichii, inhibited the proliferation of L. amazonensis in vitro and the i.p. adminis-
tration of 100 mg/kg/day is sufficient to prevent lesion development and to reduce parasite
burden in vivo [51].
Furthermore, plants synthesize chalcones which are structurally related to the cinnamic
acid derivatives tested in our study. Chalcones are precursors for flavonoids which are part of
the biological defense mechanisms against plant pathogens [52]. Chalcones show antibacterial
[53], antimalarial [54] and antileishmanial [55] activities among others. In vitro, the antileish-
manial activity of chalcones isolated from Chinese licorice against L.major and L. donovani is
related to mitochondrial alterations [56]. Synthetic analogues of chalcone isolates of Crotalaria
ramosissima show enhanced in vitro and in vivo activity as compared to the natural chalcone
[57]. Antileishmanial in vivo activity of chalcones is demonstrated against L. donovani infec-
tions in hamster and against the predominant causative agent of leishmaniasis in Latin Amer-
ica, L. braziliensis [55, 56]. Natural or synthesized compounds with structural similarities, like
cinnamic acid derivatives and chalcones, show activity against a broad range of Leishmania
parasites, indicating their potential as lead structures for the development of chemotherapeutic
approaches against Leishmania infections. However, the structure of chalcones and cinnamic
acid derivatives comprises a reactive Michael system, which is prone to unselective attacks by
nucleophilic groups of proteins e.g. thiol groups of the amino acid cysteine or glutathione,
thereby being able to give false-positive activity which is regarded as a PAINS problem [58].
To summarize, the process of the identification and evaluation of the antileishmanial com-
pounds 1 and 2 started with the fractionation of crude root extracts from V. wallichii, a well-
known plant used in traditional medicine. A semi-pure fraction of a chloroform extract was
found to exhibit leishmanicidal in vitro activity against L.major and L. donovani [10]. Subse-
quent studies identified caffeic acid bornyl ester with antileishmanial in vitro activity [11]. SAR
studies prompted the synthesis of less toxic but leishmanicidal compounds relying on the origi-
nally extracted structure from V. wallichii [12]. To eliminate possible unselective effects due to
the reactive Michael system of cinnamic acid, compound 2 was synthesized without this moi-
ety. Thus, cytotoxicity was reduced while antileishmanial activity was preserved. The successful
evaluation of this compound in an experimental mouse model against L.major infections is an
important step in the lead optimization and development. Preliminary studies in L. donovani
infected BALB/c mice treated with the compounds 1 and 2 showed also promising antileishma-
nial in vivo activities, but need further evaluation. Primarily the hydrocinnamic acid derivative
(2) shows promising in vitro activity while affecting and altering the mitochondria of
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Leishmania, making it a potent lead structure for the development of antileishmanial chemo-
therapeutic approaches.
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